Mannkind corporation mnkd was founded in the early 2000s by the late alfred mann, a physicist by training, mann was a pioneer in several fields including aerospace, electronics and medical devices. Mannkind regains commercial rights to afrezza, begins sales and marketing efforts. Amsl, to also file afrezza there this year in the first half of 2021, if we can. Mannkind corporation reports 2020 third quarter financial. Mnkd q4 2020 earnings conference call feb 25, 2020, 09. Technosphere insulin now afrezza receives fda approval. Afrezza was considered more convenient than exubera. The registration dossier includes recently updated prescribing information for afrezza, incorporating new clinical data describing the rapid timeaction profile of afrezza. Afrezza uhfrezzuh insulin human inhalation powder what. Dec 14, 2012 afrezza can reduce lung function, so your doctor will also want to test your breathing 6 months after starting afrezza, and then each year after that, with more frequent testing done if you have symptoms such as wheezing or coughing.
The use of afrezza is not recommended in patients who smoke or who have recently stopped smoking. Mannkind corporation mnkd ceo mike castagna presents at. Mnkd, is expected to launch its lead product afrezza, an inhalable form of insulin. Mannkind will present a poster with initial information from its ongoing study of safety and pharmacokinetics of technosphere insulin afrezza in pediatric patients. By addressing the sales objections that stymied sanofis efforts, mannkind will easily generate more. Aug 19, 20 meanwhile, we expect investor focus to remain on afrezza going forward. At this time, mannkind does not anticipate that the supply of its inhalable insulin afrezza insulin human inhalation powder will be affected by the coronavirus. Jun 24, 2016 if sanofi had gotten 150,000 patients on afrezza, mannkind s future would not be in doubt. Afrezza is an ultra rapidacting inhaled insulin used to improve glycemic. Shortly thereafter, sanofi, a company with vast experience in the diabetic space, became mannkind s marketing partner and helped launch afrezza in february, 2015. Afrezza lowers blood sugars rapidly, similar to the insulin response of a person without diabetes. Fda updates afrezza prescribing information mannkind.
It is not known if afrezza is safe and effective for use in people who smoke. Can tyvasos potential approval prove transformative for. Article information, pdf download for technosphere insulin afrezza open epub for. Mannkind corporation reports 2020 first quarter financial results. Mannkind corporation is a biopharmaceutical company focusing on the discovery. The afrezza inhalation system is a drugdelivery device combination product. A novel, rapidacting inhaled insulin for the treatment of diabetes. Mannkind corporation mnkd ceo michael castagna presents at.
Afrezza insulin human inhalation powder prescribing information. Mannkind has been able to bring his idea of a dry powder insulin formulation to fruition through afrezza, the companys flagship product. Afrezza is administered using a single inhalation per cartridge. It also significantly decreased daytime glucose variability. Afrezza is not for use in people who smoke or have recently stopped smoking less than 6 months. Mannkind corporation announces fda approval of afrezzar. Mannkind corporation application no 022472 approval date. It is not known if afrezza is safe and effective in children under 18 years of age. On march 16, 2009, mannkind issued a press release announcing that it 24 had submitted an nda to the fda for approval of thencalled afresa insulin. Mannkind corporation 20182019 5 dispense afrezza insulin human inhalation powder as follows. Dailymed afrezza insulin human powder, metered afrezza. Persons with disabilities having problems accessing the pdf files below may call 301 7963634 for.
Improved postprandial glucose with inhaled technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections. Jun 27, 2014 mannkind corporation announces fda approval of afrezza r. Feb 04, 2021 heading into 2020s final stretch, mannkind mnkd shares built up steam which cemented the diabetes specialists turnaround after a multiyear slump. Mannkind websites are designed to provide information and resources to those who use them. Mannkind corporation mnkd ceo michael castagna on q4 2020. Mannkind is also pursuing commercialization in india and brazil. We are excited to file our first international application for approval of afrezza in brazil, which is in the top ten countries with the highest diabetes rates in the world. Mannkind presents positive afrezza clinical data from three. No needlesticks afrezza is an innovative solution that gives you mealtime glucose control. Afrezza is not for use to treat diabetic ketoacidosis. Additional phase 3 studies of technosphere insulin conducted using nextgeneration inhaler dreamboat. Rethinking the viability and utility of inhaled insulin in clinical practice. With the spread of the coronavirus, many individuals are concerned about access to their medication supply. Thus, 21 assuming it was approved, mannkind was able to generate substantial investor 22 enthusiasm for the product.
Afrezza is a manmade insulin that is breathedin through your lungs inhaled and is used to control high blood sugar in adults with diabetes mellitus. Wainwright global life sciences conference march 09, 2021 07. Fda updates afrezza prescribing information nasdaq. Mannkind now plans to file the amended new drug application to the fda for the candidate in early fourth quarter of 20. Mar 22, 2021 afrezza is a manmade insulin that is breathedin through your lungs inhaled and is used to control high blood sugar in adults with diabetes mellitus. Afrezza technosphere insulin inhalation system, 3 unit and 6 unit cartridges for oral inhalation, manufactured by mannkind. Other analysts also recently issued reports about the stock. We expect to file further patent applications as our research and. Among his successes prior to mannkind was development of the first rechargeable pacemaker and minimed, a revolutionary miniaturized. In a recent study 3 stat study study comparing prandial insulin aspart vs. The firm has developed afrezza a rapidacting insulin peaking 12 to 15 minutes after. Did mannkind misjudge consumer demand, or are barriers from payers to. Mnkd oppenheimers 31st annual healthcare conference march 17, 2020 1. Persons with disabilities having problems accessing the pdf files below may call 301 7963634 for assistance.
Cantor fitzgerald reiterated an overweight rating on shares of mannkind in a report on thursday, november 5th. Acute bronchospasm has been observed in patients with asthma and copd using afrezza afrezza is contraindicated in patients with chronic lung disease such as asthma or copd before initiating afrezza, perform a detailed medical history, physical examination, and. Aug 03, 2018 given the growing possibility that mannkind will finally be forced to admit the obvious that its inhaled insulin product afrezza is a commercial flop and subsequently file for bankruptcy, i. The plaintiffs in this consolidated class action allege that mannkind and. Health care is a personal matter, and mannkind maintains that level of privacy and confidentiality necessary to allow patients, health care professionals, caregivers and others to use our websites with confidence.
No planning afrezza lets you inhale your insulin right when food arriveseven unexpectedly so you can be spontaneous but still in control. This study is the first step in preparation for a phase 3 safety and efficacy study. The company anticipates a regulatory filing for afrezza in canada in 1h 2019 and in e. As the global situation evolves, we will continue to take the necessary steps to safeguard the reliable supply of afrezza. Path to afrezza survival involves lower prices to woo. Mannkind corporation mnkd q4 2020 earnings call transcript. Wainwright bioconnect 2021 conference january, 11 2021, 06. Formulation work commences on treprostinil technosphere tret. Mannkind and biomm submit registration dossier to brazilian. An underutilized manufacturing facility is one of the key elements that impacts costs and expanding the customer base internationally should help reduce. Mnkd files an 8k creation of a direct financial obligation or an obligation under an offbalance sheet arrangement of a registrantitem 2. Afrezza is not for use in place of longacting insulin. Afrezza prior authorization with quantity limit program summary.
249 538 1581 1504 516 967 214 1205 147 1820 384 785 691 239 1561 167 1006 902 207 437